Regeneron Pharmaceuticals (REGN) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Regeneron Pharmaceuticals, Inc. (REGN) insider buying and selling: no purchases, 17 sales
73 Form 4 Table I transactions filed with the SEC by Regeneron Pharmaceuticals, Inc. insiders between 2025-10-31 and 2026-10-15 (15-month history): 0 open-market purchases and 17 sales, plus 56 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $4.3M by Poon Christine A on 2025-10-29.
Regeneron Pharmaceuticals insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Regeneron Pharmaceuticals insiders filed 17 sales worth $16.1M on the open market, and no purchases.
The biggest seller was Poon Christine A (Director): $4.3M in 1 sale, out of 8 different sellers.
The largest trade of the period was a sale of $4.3M on Oct 29, 2025, by Poon Christine A (Director). Form 4 on sec.gov (0001189014-25-000005).
Of the 17 sales, 15 (88%, $11.6M) carry the 10b5-1 plan flag on the Form 4, meaning they were scheduled months ahead; the other 2 do not.
The last three months show 6 sales, against 2 in the three before. The latest sale from Oct 14, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Regeneron Pharmaceuticals has more sales than 43 of the other 58, ranks 29 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with REGN's sales, largest first. The full history is in the tool above, already searched.
See all 73 REGN trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2025-10-29 | 2025-10-31 | Poon Christine A | Director | $4.3M | S — Open-market sale6 Form 4 footnotesF1 Represents volume-weighted average price of sales of 650 shares of Company stock on October 29, 2025 at prices ranging from $652.31 to $652.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price. F2 Represents volume-weighted average price of sales of 2,735 shares of Company stock on October 29, 2025 at prices ranging from $653.05 to $653.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price. F3 Represents volume-weighted average price of sales of 1,915 shares of Company stock on October 29, 2025 at prices ranging from $654.01 to $654.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price. F4 Represents volume-weighted average price of sales of 100 shares of Company stock on October 29, 2025 at prices ranging from $655.02 to $655.16. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price. F5 Represents volume-weighted average price of sales of 712 shares of Company stock on October 29, 2025 at prices ranging from $656.33 to $656.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price. F6 Represents volume-weighted average price of sales of 388 shares of Company stock on October 29, 2025 at prices ranging from $657.02 to $657.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price. | SEC |
| 2026-10-14 | 2026-10-15 | Murphy Andrew J | Co-Chief Scientific Officer | $3.2M | S — Open-market sale (scheduled 10b5-1)22 Form 4 footnotesF1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 7, 2026. F2 Represents volume-weighted average price of sales of 14 shares of Company stock on October 14, 2026 at prices ranging from $759.94 to $759.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F3 Represents volume-weighted average price of sales of 74 shares of Company stock on October 14, 2026 at prices ranging from $760.28 to $760.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F4 Represents volume-weighted average price of sales of 27 shares of Company stock on October 14, 2026 at prices ranging from $761.01 to $761.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F5 Represents volume-weighted average price of sales of 25 shares of Company stock on October 14, 2026 at prices ranging from $763.62 to $763.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F6 Represents volume-weighted average price of sales of 219 shares of Company stock on October 14, 2026 at prices ranging from $764.04 to $764.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F7 Represents volume-weighted average price of sales of 271 shares of Company stock on October 14, 2026 at prices ranging from $765.11 to $765.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F8 Represents volume-weighted average price of sales of 279 shares of Company stock on October 14, 2026 at prices ranging from $766.00 to $766.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F9 Represents volume-weighted average price of sales of 192 shares of Company stock on October 14, 2026 at prices ranging from $767.10 to $767.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F10 Represents volume-weighted average price of sales of 105 shares of Company stock on October 14, 2026 at prices ranging from $768.15 to $768.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F11 Represents volume-weighted average price of sales of 127 shares of Company stock on October 14, 2026 at prices ranging from $769.15 to $769.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F12 Represents volume-weighted average price of sales of 283 shares of Company stock on October 14, 2026 at prices ranging from $771.04 to $771.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F13 Represents volume-weighted average price of sales of 211 shares of Company stock on October 14, 2026 at prices ranging from $772.06 to $772.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F14 Represents volume-weighted average price of sales of 224 shares of Company stock on October 14, 2026 at prices ranging from $773.14 to $773.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F15 Represents volume-weighted average price of sales of 121 shares of Company stock on October 14, 2026 at prices ranging from $774.11 to $774.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F16 Represents volume-weighted average price of sales of 376 shares of Company stock on October 14, 2026 at prices ranging from $775.14 to $775.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F17 Represents volume-weighted average price of sales of 66 shares of Company stock on October 14, 2026 at prices ranging from $776.00 to $776.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F18 Represents volume-weighted average price of sales of 38 shares of Company stock on October 14, 2026 at prices ranging from $777.51 to $777.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F19 Represents volume-weighted average price of sales of 454 shares of Company stock on October 14, 2026 at prices ranging from $778.05 to $778.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F20 Represents volume-weighted average price of sales of 380 shares of Company stock on October 14, 2026 at prices ranging from $779.00 to $779.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F21 Represents volume-weighted average price of sales of 463 shares of Company stock on October 14, 2026 at prices ranging from $780.06 to $780.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. F22 Represents volume-weighted average price of sales of 50 shares of Company stock on October 14, 2026 at prices ranging from $781.05 to $781.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price. | SEC |
| 2026-02-09 | 2026-02-11 | Pitofsky Jason | SVP Controller | $1.6M | S — Open-market sale (scheduled 10b5-1)10 Form 4 footnotesF1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025. F2 Represents volume-weighted average price of sales of 521 shares of Company stock on February 9, 2026 at prices ranging from $776.05 to $776.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. F3 Represents volume-weighted average price of sales of 391 shares of Company stock on February 9, 2026 at prices ranging from $777.33 to $777.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. F4 Represents volume-weighted average price of sales of 563 shares of Company stock on February 9, 2026 at prices ranging from $778.00 to $778.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. F5 Represents volume-weighted average price of sales of 205 shares of Company stock on February 9, 2026 at prices ranging from $779.19 to $779.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. F6 Represents volume-weighted average price of sales of 75 shares of Company stock on February 9, 2026 at prices ranging from $780.03 to $780.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. F7 Represents volume-weighted average price of sales of 26 shares of Company stock on February 9, 2026 at prices ranging from $781.18 to $781.53. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. F8 Represents volume-weighted average price of sales of 37 shares of Company stock on February 9, 2026 at prices ranging from $782.22 to $782.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. F9 Represents volume-weighted average price of sales of 144 shares of Company stock on February 9, 2026 at prices ranging from $783.17 to $783.29. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. F10 Represents volume-weighted average price of sales of 53 shares of Company stock on February 9, 2026 at prices ranging from $785.72 to $785.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. | SEC |
| 2026-02-19 | 2026-02-23 | Zoghbi Huda Y | Director | $1.3M | S — Open-market sale (scheduled 10b5-1)9 Form 4 footnotesF1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. F2 Represents volume-weighted average price of sales of 53 shares of Company stock on February 19, 2026 at prices ranging from $778.46 to $778.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. F3 Represents volume-weighted average price of sales of 208 shares of Company stock on February 19, 2026 at prices ranging from $779.10 to $779.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. F4 Represents volume-weighted average price of sales of 331 shares of Company stock on February 19, 2026 at prices ranging from $780.06 to $780.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. F5 Represents volume-weighted average price of sales of 209 shares of Company stock on February 19, 2026 at prices ranging from $781.10 to $781.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. F6 Represents volume-weighted average price of sales of 298 shares of Company stock on February 19, 2026 at prices ranging from $782.01 to $782.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. F7 Represents volume-weighted average price of sales of 220 shares of Company stock on February 19, 2026 at prices ranging from $783.00 to $783.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. F8 Represents volume-weighted average price of sales of 160 shares of Company stock on February 19, 2026 at prices ranging from $784.14 to $784.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. F9 Represents volume-weighted average price of sales of 56 shares of Company stock on February 19, 2026 at prices ranging from $785.60 to $785.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 19, 2026 at each separate price. | SEC |
| 2026-01-07 | 2026-01-08 | Bassler Bonnie L | Director | $1.2M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025. F2 Represents volume-weighted average price of sales of 1,500 shares of Company stock on January 7, 2026 at prices ranging from $800.00 to $800.01. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 7, 2026 at each separate price. | SEC |
| 2026-09-02 | 2026-09-03 | Mccourt Marion | EVP Commercial | $1.0M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026. | SEC |
| 2026-09-03 | 2026-09-03 | Mccourt Marion | EVP Commercial | $970k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026. | SEC |
| 2026-08-10 | 2026-08-12 | Zoghbi Huda Y | Director | $640k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. | SEC |
| 2025-11-20 | 2025-11-24 | Bassler Bonnie L | Director | $570k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025. | SEC |
| 2026-09-02 | 2026-09-03 | Guarini Kathryn | Director | $340k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026. | SEC |
| 2026-08-10 | 2026-08-12 | Guarini Kathryn | Director | $320k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2026. | SEC |
| 2025-11-07 | 2025-11-10 | Pitofsky Jason | VP Controller | $281k | S — Open-market sale | SEC |
| 2026-07-02 | 2026-07-07 | Ryan Arthur F | Director | $130k | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2 Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price. | SEC |
| 2026-03-02 | 2026-03-03 | Ryan Arthur F | Director | $79k | S — Open-market sale (scheduled 10b5-1)13 Form 4 footnotesF1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2 Represents volume-weighted average price of sales of 7 shares of Company stock on March 2, 2026 at prices ranging from $777.08 to $777.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. F3 Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $778.27 to $778.33. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. F4 Represents volume-weighted average price of sales of 5 shares of Company stock on March 2, 2026 at prices ranging from $779.36 to $779.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. F5 Represents volume-weighted average price of sales of 3 shares of Company stock on March 2, 2026 at prices ranging from $780.13 to $780.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. F6 Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $781.00 to $781.42. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. F7 Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $782.25 to $782.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. F8 Represents volume-weighted average price of sales of 10 shares of Company stock on March 2, 2026 at prices ranging from $783.25 to $783.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. F9 Represents volume-weighted average price of sales of 9 shares of Company stock on March 2, 2026 at prices ranging from $784.02 to $784.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. F10 Represents volume-weighted average price of sales of 11 shares of Company stock on March 2, 2026 at prices ranging from $785.02 to $785.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. F11 Represents volume-weighted average price of sales of 7 shares of Company stock on March 2, 2026 at prices ranging from $786.12 to $786.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. F12 Represents volume-weighted average price of sales of 2 shares of Company stock on March 2, 2026 at prices ranging from $787.02 to $787.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. F13 Represents volume-weighted average price of sales of 20 shares of Company stock on March 2, 2026 at prices ranging from $789.27 to $789.37. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 2, 2026 at each separate price. | SEC |
| 2026-02-09 | 2026-02-11 | Ryan Arthur F | Director | $78k | S — Open-market sale (scheduled 10b5-1)7 Form 4 footnotesF1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2 Represents volume-weighted average price of sales of 10 shares of Company stock on February 9, 2026 at prices ranging from $776.04 to $776.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. F3 Represents volume-weighted average price of sales of 57 shares of Company stock on February 9, 2026 at prices ranging from $777.02 to $777.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. F4 Represents volume-weighted average price of sales of 12 shares of Company stock on February 9, 2026 at prices ranging from $778.11 to $778.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. F5 Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $779.13 to $779.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. F6 Represents volume-weighted average price of sales of 5 shares of Company stock on February 9, 2026 at prices ranging from $781.05 to $781.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. F7 Represents volume-weighted average price of sales of 3 shares of Company stock on February 9, 2026 at prices ranging from $783.20 to $783.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price. | SEC |
| 2026-04-01 | 2026-04-03 | Ryan Arthur F | Director | $78k | S — Open-market sale (scheduled 10b5-1)9 Form 4 footnotesF1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2 Represents volume-weighted average price of sales of 3 shares of Company stock on April 1, 2026 at prices ranging from $772.62 to $772.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. F3 Represents volume-weighted average price of sales of 8 shares of Company stock on April 1, 2026 at prices ranging from $773.27 to $773.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. F4 Represents volume-weighted average price of sales of 8 shares of Company stock on April 1, 2026 at prices ranging from $774.05 to $774.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. F5 Represents volume-weighted average price of sales of 14 shares of Company stock on April 1, 2026 at prices ranging from $775.04 to $775.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. F6 Represents volume-weighted average price of sales of 13 shares of Company stock on April 1, 2026 at prices ranging from $776.11 to $776.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. F7 Represents volume-weighted average price of sales of 9 shares of Company stock on April 1, 2026 at prices ranging from $777.03 to $777.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. F8 Represents volume-weighted average price of sales of 4 shares of Company stock on April 1, 2026 at prices ranging from $778.02 to $778.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. F9 Represents volume-weighted average price of sales of 40 shares of Company stock on April 1, 2026 at prices ranging from $779.65 to $779.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2026 at each separate price. | SEC |
| 2026-05-01 | 2026-05-04 | Ryan Arthur F | Director | $71k | S — Open-market sale (scheduled 10b5-1)12 Form 4 footnotesF1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2 Represents volume-weighted average price of sales of 5 shares of Company stock on May 1, 2026 at prices ranging from $701.36 to $701.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. F3 Represents volume-weighted average price of sales of 15 shares of Company stock on May 1, 2026 at prices ranging from $702.02 to $702.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. F4 Represents volume-weighted average price of sales of 24 shares of Company stock on May 1, 2026 at prices ranging from $703.01 to $703.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. F5 Represents volume-weighted average price of sales of 15 shares of Company stock on May 1, 2026 at prices ranging from $704.01 to $704.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. F6 Represents volume-weighted average price of sales of 14 shares of Company stock on May 1, 2026 at prices ranging from $705.02 to $705.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. F7 Represents volume-weighted average price of sales of 7 shares of Company stock on May 1, 2026 at prices ranging from $706.05 to $706.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. F8 Represents volume-weighted average price of sales of 4 shares of Company stock on May 1, 2026 at prices ranging from $707.12 to $707.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. F9 Represents volume-weighted average price of sales of 6 shares of Company stock on May 1, 2026 at prices ranging from $709.05 to $709.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. F10 Represents volume-weighted average price of sales of 2 shares of Company stock on May 1, 2026 at prices ranging from $710.86 to $710.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. F11 Represents volume-weighted average price of sales of 5 shares of Company stock on May 1, 2026 at prices ranging from $711.17 to $711.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. F12 Represents volume-weighted average price of sales of 2 shares of Company stock on May 1, 2026 at prices ranging from $714.12 to $714.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price. | SEC |
| 2025-12-09 | 2025-12-11 | Schleifer Leonard S | Bd. Co-Chair, President & CEO | $108.8M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2025-12-09 | 2025-12-11 | Schleifer Leonard S | Bd. Co-Chair, President & CEO | $96.0M | M — Option exercise | SEC |
| 2025-12-09 | 2025-12-11 | Yancopoulos George | Bd. Co-Chair, President & CSO | $92.5M | F — Tax withholding (shares surrendered for taxes) | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Oct 31, 2025 and Oct 15, 2026 there is not one open-market purchase of Regeneron Pharmaceuticals, Inc.: 17 sales worth $16.1M and zero dollars bought.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Regeneron Pharmaceuticals, Inc.'s is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| F | Tax withholding (shares surrendered for taxes) | 19 | $313.0M |
| M | Option exercise | 19 | $231.0M |
| A | Grant or award | 17 | $0 |
| S | Open-market sale | 17 | $16.1M |
| G | Gift | 1 | $0 |
| Total | Everything filed in the period | 73 | $560.1M |
20 of the 73 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 19 distinct people or entities have filed Regeneron Pharmaceuticals, Inc. transactions: none bought on the open market and 8 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 8 who sold on the open market (17 sales in all), the three biggest sellers account for $9.5M of the $16.1M: 59% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Poon Christine A | Director | 4 | — | $4.3M (1) | 2026-01-06 |
| Murphy Andrew J | Co-Chief Scientific Officer | 9 | — | $3.2M (1) | 2026-10-15 |
| Mccourt Marion | EVP Commercial | 5 | — | $2.0M (2) | 2026-09-03 |
| Zoghbi Huda Y | Director | 5 | — | $1.9M (2) | 2026-08-12 |
| Pitofsky Jason | SVP Controller | 5 | — | $1.9M (2) | 2026-02-11 |
| Bassler Bonnie L | Director | 5 | — | $1.8M (2) | 2026-01-08 |
| Guarini Kathryn | Director | 5 | — | $660k (2) | 2026-09-03 |
| Ryan Arthur F | Director | 6 | — | $435k (5) | 2026-07-07 |
Shown here are the 8 who moved the most money, out of 19. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Feb 2026: 0 purchases and 3 sales, worth $2.9M. 4 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 0 | $0 |
| Oct 2025 | 0 | $0 | 1 | $4.3M |
| Nov 2025 | 0 | $0 | 2 | $851k |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 1 | $1.2M |
| Feb 2026 | 0 | $0 | 3 | $2.9M |
| Mar 2026 | 0 | $0 | 1 | $79k |
| Apr 2026 | 0 | $0 | 1 | $78k |
| May 2026 | 0 | $0 | 1 | $71k |
| Jun 2026 | 0 | $0 | 0 | $0 |
| Jul 2026 | 0 | $0 | 1 | $130k |
| Aug 2026 | 0 | $0 | 2 | $960k |
| Sep 2026 | 0 | $0 | 3 | $2.3M |
| Oct 2026 | 0 | $0 | 1 | $3.2M |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Regeneron Pharmaceuticals, Inc. (REGN) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
15 of the 17 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. Regeneron Pharmaceuticals has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Oct 15, 2026, and a Form 4 arrives up to two business days after the trade.
16 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.